PDCD1 and neoplasm: IFN-γ secretion of CD8+ T cells represents the activity and anti-tumor ability; thus, patients with high PD-1+ IFN-γ+ cell percentages of CD8+ T cells at baseline tend to benefit from PD-1 therapy.